Latest news with #InVitroDiagnosticsBusinessOutlook
Malaysian Reserve
16 hours ago
- Business
- Malaysian Reserve
Infectious Disease Testing Market Remains Dynamic Amid Post-Pandemic Shifts and New Innovations
ARLINGTON, Va., June 19, 2025 /PRNewswire/ — Kalorama Information, a trusted source for healthcare market intelligence, released insights into the evolving global market for infectious disease testing through the In Vitro Diagnostics Business Outlook newsletter. Despite the decline in COVID-19 testing, the overall infectious disease diagnostics market remains robust, supported by sustained demand for non-COVID tests and the adoption of next-generation technologies across both laboratory and point-of-care (POC) settings. With testing essential for diagnosing, monitoring, and containing a wide range of infections—from respiratory illnesses and bloodborne viruses to sepsis and gastrointestinal pathogens—the market continues to attract significant attention and investment. Kalorama's latest report highlights a steady shift in growth drivers, with POC solutions, molecular platforms, and advanced immunoassays gaining ground. 'Infectious disease diagnostics continues to be one of the most innovative segments of the IVD industry,' said Daniel Granderson, Senior Editor of Kalorama Information. 'New technologies are not only enhancing diagnostic speed and accuracy but are also reshaping where and how testing is performed—bringing more solutions to decentralized and resource-limited settings.' Highlights from the article include: Strong global demand for lab-based immunoassays and molecular tests Continued innovation in syndromic panels, microfluidics, and cartridge-based POC platforms A growing share of the market shifting toward emerging regions, with Asia Pacific and other developing areas seeing increased diagnostic infrastructure and demand Major industry players—including Roche, Abbott, Danaher, and QIAGEN—introducing new products to address unmet needs in STIs, sepsis, and respiratory diseases The report also profiles emerging innovators bringing AI-powered diagnostics, rapid sepsis panels, and cost-effective molecular tools to market, emphasizing the industry's ongoing focus on speed, accuracy, and accessibility. For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook. About IVD Business Outlook In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Website:
Yahoo
2 days ago
- Business
- Yahoo
Cardiac Marker Testing Market Poised for Steady Growth, Driven by Point-of-Care Expansion
ARLINGTON, Va., June 18, 2025 /PRNewswire/ -- The global cardiac marker testing market is on track for sustained growth, according to research from Kalorama Information's IVD Business Outlook. As cardiovascular disease remains a leading cause of mortality worldwide, demand for rapid and accurate diagnostic testing continues to rise. Kalorama's latest analysis highlights that while traditional lab-based cardiac marker testing remains the dominant segment, the point-of-care (POC) segment is gaining ground at a faster pace—reflecting growing interest in decentralized and near-patient diagnostics. The article projects continued market expansion through 2029, supported by adoption of high-sensitivity assays and increasing procedure volumes globally. "The shift toward point-of-care cardiac testing reflects a broader transformation in healthcare delivery," said Daniel Granderson, Senior Editor of Kalorama Information. "Providers are seeking faster diagnostic tools that enable quicker clinical decisions, especially in emergency and acute care settings." Cardiac biomarkers such as troponin, BNP, CK-MB, and myoglobin remain central to acute care diagnostics, accounting for the vast majority of test volumes. North America and Europe collectively account for more than three-quarters of global market share, while the Asia Pacific region continues to emerge as a high-potential growth area. The article also profiles major players shaping the market landscape, including Danaher (via Beckman Coulter and Radiometer), Siemens Healthineers, QuidelOrtho, Roche, and Abbott. Recent product launches, regulatory approvals, and shifts in diagnostic testing demand—particularly post-pandemic—are helping to reshape vendor dynamics and innovation priorities. For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook. About IVD Business OutlookIn Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Infectious Disease Testing Surges to $29B: Kalorama Report Highlights Molecular Breakthroughs and Point-of-Care Growth in IVD Market
ARLINGTON, Va., June 17, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market intelligence, has released the latest edition of its bimonthly publication, In Vitro Diagnostics Business Outlook. Now in its fourth year, the most recent issue is a comprehensive market briefing offering exclusive insights into the evolving landscape of infectious disease testing—one of the most dynamic sectors within the global in vitro diagnostics (IVD) market. Previous issues have covered key IVD topics including cardiac biomarkers, glucose testing, point-of-care testing, blood screening, clinical chemistry, molecular HLA testing, and more. According to the latest issue, the infectious disease testing market reached an estimated $29 billion in 2024, with COVID-19 testing accounting for 18% of total revenue, even as demand declines post-pandemic. Non-COVID point-of-care (POC) testing continued its upward trajectory, increasing by mid-single digits, and the segment remains a critical driver of diagnostic innovation globally. "The infectious disease testing market is highly concentrated in North American and European markets, with a combined share exceeding three-quarters of the global market," said Daniel Granderson, Senior Editor at Kalorama Information. "However, distribution is slowly shifting as emerging markets ramp up adoption of molecular platforms and POC innovations." The report highlights the growing impact of next-generation technologies, including alternative PCR methods, microarrays, NGS, and mass spectrometry. Instrument-automated analysis and miniaturized platforms are enabling broader deployment across physician offices, mobile health clinics, and even home settings—marking a transformational shift in test accessibility. Other key insights from this edition: Molecular diagnostics remain concentrated in developed countries but show new growth in Latin America, Southeast Asia, and Africa. Point-of-care testing is increasingly pivoting to non-COVID applications, such as respiratory panels, STIs, and antimicrobial resistance surveillance. Investment, M&A, and R&D activity remain robust across diagnostic segments, as companies reorient toward long-term growth drivers beyond pandemic response. A Strategic Resource for Healthcare Decision-Makers In Vitro Diagnostics Business Outlook delivers six issues annually, each exploring a high-value IVD market segment. It is designed for: Corporate strategy teams seeking growth forecasts and pipeline planning data R&D and innovation leads tracking platform adoption and market shifts Investors and financial analysts evaluating diagnostic business models and M&A targets Clinical lab leaders and health policy experts seeking diagnostic utilization trends and access insights Each issue includes: Market forecasts, growth rates, and share analysis Company and product profiles M&A and partnership tracking Geographic and regulatory trends Expert commentary and exclusive news analysis Order Now The full report can be purchased at: For purchase or custom consultation, contact:Sheri Davie, Sales About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website. View original content to download multimedia: SOURCE Kalorama Information Sign in to access your portfolio
